

Listing of Claims

1. – 48. (Cancelled)

49. (Currently amended) A method of expressing ~~delivering~~ a therapeutic or an antigenic protein or peptide in to an individual, the method comprising:

administering to the individual an effective amount of a ~~chimaeric~~ chimeric virus comprising a heterologous nucleic acid sequence encoding the therapeutic or the antigenic protein or peptide wherein the nucleic acid sequence is under control of an expression control sequence, or a pharmaceutical composition thereof, wherein the ~~chimaeric~~ chimeric virus is produced by a method comprising culturing a host cell which comprises:

~~one or more~~ a Simian Immunodeficiency Virus (SIV) Gag-Pol nucleic acid sequence[[s]] under control of an expression control sequence, wherein said SIV Gag-Pol nucleic acid sequence[[s]] encode[[s]] an SIV capsid,

~~and which further comprises a vector comprising a Human Immunodeficiency Virus type 2 (HIV-2) packaging signal and the heterologous nucleic acid sequence,~~

SIV accessory genes necessary for viral assembly, and

an envelope coding sequence under control of expression control sequences;

wherein said culturing results in said vector being packaged in the SIV capsid to produce the ~~chimaeric~~ chimeric virus.

50. (Previously presented) The method according to claim 49 wherein the individual is a human or non-human primate.